Skip to main content
. 2017 Jun 8;57(3):87–97. doi: 10.3960/jslrt.17008

Table 3. Outcomes from chemotherapies in aggressive ATL.

graphic file with name jslrt-57-87-t003.jpg

*: data not shown, estimated from graphics.

Abbreviations: NA, not available; allo-HSCT, allogeneic-hematopoietic stem cell transplantation; MST, median survival time; OS, overall survival; VEPA, consisting of vincristine, cyclophosphamide, prednisone, and doxorubicin; MTX, methotrexate; DCF, Deoxycoformycin; CHOP, consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone; VCAP-AMP-VECP, sequential combination chemotherapy consisting of VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisolone), AMP (doxorubicin, ranimustine, and prednisolone), and VECP (vindesine, etoposide, carboplatin, and prednisolone); JCOG, Japan Clinical Oncology Group